Israel - anglès - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - irinotecan hydrochloride - solution for infusion - irinotecan hydrochloride 20 mg/ml - irinotecan - irinotecan - campto is indicated for the treatment of patients with metastatic colorectal cancer: in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer.irinotecan in combination with leucovorin, oxaliplatin and 5-fluorouracil for the first-line treatment of patients with metastatic pancreatic adenocarcinoma.

Namíbia - anglès - Namibia Medicines Regulatory Council

pharmaco distribution (pty) ltd - 5-fluorouracil - ointment - each 100g ointment contains: 5-fluorouracil 5g

Namíbia - anglès - Namibia Medicines Regulatory Council

teva pharmaceuticals (pty) ltd - 5-fluorouracil - injection - each 5,0 ml solution contains; 5-fluorouracil 250 mg

Namíbia - anglès - Namibia Medicines Regulatory Council

teva pharmaceuticals (pty) ltd - 5-fluorouracil - injection - each 10,0 ml solution contains; 5-fluorouracil 500 mg

Namíbia - anglès - Namibia Medicines Regulatory Council

teva pharmaceuticals (pty) ltd - 5-fluorouracil - injection - each 20,0 ml solution contains; 5-fluorouracil 1,000 mg

Namíbia - anglès - Namibia Medicines Regulatory Council

teva pharmaceuticals (pty) ltd - 5-fluorouracil - injection - each 100,0 ml solution contains; 5-fluorouracil 5,000 mg

Egipte - anglès - EDA (Egyptian Drug Authority)

egyptian pharmaceutical trading company - injection - 250 mg/5ml

Egipte - anglès - EDA (Egyptian Drug Authority)

b.p pharma - injection - 1000 mg

Egipte - anglès - EDA (Egyptian Drug Authority)

b.p pharma - injection - 500 mg

Egipte - anglès - EDA (Egyptian Drug Authority)

b.p pharma - injection - 50 mg/ml